- ASH Annual Meeting Exposition - Hematology. org
ASH is committed to creating an inclusive meeting environment where all individuals feel comfortable, safe, and welcome regardless of background, identity, or disability If you have any concerns or need information on navigating this year’s annual meeting in Orlando, contact meetings@hematology org to arrange to speak to staff who can assist
- 66th ASH Annual Meeting
You may search for particular presentations by typing key words, an author's name, or the title in the box below You may specify the type of search, i e whether you want to see pages that contain any or all of the words you specify The Boolean search option requires one of the keywords and, or, and not, as well as parentheses
- Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition
Key Takeaways The ASH Annual Meeting will showcase new therapies, emerging data, and scientific insights in hematology, with a focus on multiple myeloma, leukemia, and sickle cell disease Pharmacy Times will report on late-breaking abstracts, clinical trial findings, and new research, including interviews with leading hematologist-oncologists
- ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
The meeting will highlight bispecific antibodies and "off the shelf" CAR T-cell therapies, potentially transforming treatment paradigms Fixed-duration therapies are gaining attention for their
- 4 notable presentations from ASH 2025 - MD Anderson Cancer Center
At the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition, they are sharing their latest research with colleagues from across the globe Here are four of their latest advances that are being presented at ASH 2025
- Blood | American Society of Hematology
In this special episode, Blood editor Dr Laura Michaelis interviews Dr Arielle Langer and Blood Associate editor Dr Marc Blondon for this special Maternal Health episode In honor of the second Maternal Health compendium, both discuss their papers featured in this special collection On the CHOPping block? Rethinking initial therapy for PMBCL
- ASH25: CAR-T leaders Gilead, J J show in multiple myeloma . . . - BioSpace
CAR-T Leaders Gilead, J J Legend Tout Promising Multiple Myeloma Data Taking center stage at ASH 2025 are CAR-T therapies, a burgeoning class of treatments with difficult business prospects One company at the leading edge of this modality is Gilead, which has partnered with California’s Arcellx to advance anitocabtagene autoleucel (anito-cel)
- American Society of Hematology - Hematology. org
The 67th ASH Annual Meeting will be held virtually and in person at the Orange County Convention Center in Orlando, Florida, December 6 - 9, 2025 Registration for ASH members, non-members, groups, exhibitors, and media is now open
|